KJ-C2526

N/A

Report date: 2025/04/30 14:59:31

Base Information

Drug NameKJ-C2526
Drug Alias NameKJ-C2526
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionNKG2D ligands modulatorsT lymphocyte replacements
TargetsNKG2D ligands
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCARsgen Therapeutics Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCARsgen Therapeutics Holdings Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A